Anaplastic large cell lymphoma (ALCL) is a biologic and clinically heterogenous subtype of T-cell lymphoma. Clinically, ALCL may present as localized (primary) cutaneous disease or widespread systemic disease. These two forms of ALCL are distinct entities with different clinical and biologic features. Both types share similar histology, however, with cohesive sheets of large lymphoid cells expressing the Ki-1 (CD30) molecule. Primary cutaneous ALCL (C-ALCL) is part of the spectrum of CD30+ lymphoproliferative diseases of the skin including lymphomatoid papulosis. Using conservative measures, 5-year disease-free survival rates are > 90%. The systemic ALCL type is an aggressive lymphoma that may secondarily involve the skin, in addition to other extranodal sites. Further, systemic ALCL may be divided based on the expression of anaplastic lymphoma kinase (ALK) protein, which is activated most frequently through the nonrandom t(2;5) chromosome translocation, causing the fusion of the nucleophosmin (NPM) gene located at 5q35 to 2p23 encoding the receptor tyrosine kinase ALK. Systemic ALK+ ALCLs have improved prognosis compared with ALK-negative ALCL, although both subtypes warrant treatment with polychemotherapy. Allogeneic and, to a lesser extent, autologous stem cell transplantation play a role in relapsed disease, while the benefit of upfront transplant is not clearly defined. Treatment options for relapsed patients include agents such as pralatrexate (Folotyn) and vinblastine. In addition, a multitude of novel therapeutics are being studied, including anti-CD30 antibodies, histone deacetylase inhibitors, immunomodulatory drugs, proteasome inhibitors, and inhibitors of ALK and its downstream signaling pathways. Continued clinical trial involvement by oncologists and patients is imperative to improve the outcomes for this malignancy.
T-cell non-Hodgkin lymphomas (NHLs) represent a heterogeneous spectrum of lymphoid malignancies. While this disease is more common in Asia, there is significant geographic variation in its incidence, which has been attributed in part to risk factors such as human T-cell leukemia virus-1/2 (HTLV-1/2) and Epstein-Barr virus (EBV). In a recent international clinicopathologic lymphoma study from 22 institutions in North America, Europe, and Asia, T-cell and natural killer (NK)-cell lymphomas accounted for approximately 12% of all NHLs. The most common subtypes were peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS; 26%), angioimmunoblastic T-cell lymphoma (AITL; 19%), NK/T-cell (10%), adult T-cell leukemia/lymphoma (ATLL; 10%), and anaplastic large cell lymphoma (ALCL, 12%: anaplastic lymphoma kinase [ALK]-positive 6.5%; ALCL, ALK-negative 5.5%).
ALCL was first described in 1985 based on the large pleomorphic cells expressing CD30, their propensity to invade sinusoids, and the cohesive appearance of the tumor. ALCL occurs as two distinct entities—a widespread systemic disease or a localized (primary) cutaneous disease—with different clinical and biologic features.[4,5] However, both types share similar histology, with cohesive sheets of large lymphoid cells expressing the Ki-1 (CD30) molecule. In a subset of systemic ALCLs the t(2;5) chromosomal translocation occurs, which is known to cause the fusion of the nucleophosim (NPM) gene at 5q35 with the receptor tyrosine kinase ALK gene at 2p23 encoding the NPM-ALK fusion protein.[6-9] The updated World Health Organization (WHO) classification of hematopoietic tumors and lymphoid tissues now recognize this subclassification, dividing systemic ALCL into ALK-positive and ALK-negative disease.
This article will provide a comprehensive review of the morphologic, immunologic, and molecular pathologic features of primary cutaneous-ALCL (C-ALCL) and systemic ALCL, including implications for prognosis. We will also describe standard and newer treatment approaches for patients with ALCL.
Clinical and Prognostic Features
Primary C-ALCL and lymphomatoid papulosis (LyP) represent a disease spectrum of CD30-positive lymphoproliferative disorders (CD30+ LPD) with many overlapping clinical, histologic, and immunophenotypical features as systemic ALCL.[4,10,11] Primary C-ALCL accounts for approximately 9% of all cutaneous T-cell lymphomas (CTCL) and affects older patients in the sixth decade with a median age of 61 years. It has rarely been described in the pediatric population.[12,13]
LyP represents a benign, chronic recurrent, self-healing, papulonodular, and papulonecrotic CD30+ skin eruption. Although 10% to 20% of patients with LyP may develop a lymphoid malignancy, the prognosis is otherwise excellent, showing a 100% 5-year survival. Most patients with primary C-ALCL present with solitary or localized skin tumors (see Figure 1A). Generalized or multifocal lesions are seen in about 20% of the patients. Extracutaneous involvement is seen in 5% to 10% of patients at presentation and most commonly occurs with regional nodal involvement. Site of origin and ALK expression are important prognostic markers. Notably, C-ALCL lesions are known to regress spontaneously. C-ALCL patients have an excellent prognosis, with a 5-year disease-specific survival (DSS) exceeding 90%, as confirmed by several studies.[13,14] A recent report, however, describes a subset of C-ALCL patients with extensive limb disease (ELD) who have a worse treatment and survival outcome compared with patients who do not have ELD. CD30/CD56 coexpression and increased fascin levels have also been associated with disease progression in selected cases.[15,16]
ALCL, systemic type, accounts for approximately 2% to 3% of all NHLs.[17,18] Prior analyses showed that ALK+ ALCL was most frequently diagnosed in men prior to age 35 (male-to-female ratio: 3.0), while ALK-negative ALCL are usually older (median age, 61 years) with a male-to-female ratio of 0.9.[19-21] In a more recent series, Savage et al confirmed the younger median age for ALK+ vs ALK− ALCL (34 years vs 58 years, respectively, P < .001), while the male-to-female ratio was similar between ALK groups. Approximately two-thirds of patients with systemic ALCL are known to have advanced-stage disease at presentation.[9,20,21] Systemic ALCL primarily involves lymph nodes, although extranodal sites may be involved. Based on ALK status, there is a similar distribution of nodal (ALK+, 54% vs ALK–, 49%) and extranodal disease (ALK+, 19% vs ALK–, 21%), although other studies have shown more frequent extranodal disease in patients with ALK+ ALCL.[19-21] The most frequent extranodal sites in ALK– ALCL include bone, subcutaneous tissue, bone marrow, and spleen, whereas in ALK+ patients, the most common sites are skin, lung, liver, bone, and bone marrow. There are rare reports of ALCL presenting as a leukemic disease, typically occurring in children and associated with a poor prognosis. There has also been a recent association of ALCL occurring in women with breast implants. De Jong et al reported an odds ratio of 18.2 (95% confidence interval, 2.1–156.8) for ALCL associated with breast prostheses.
The impact of NPM-ALK expression on patient outcome was first observed by Shiota in 1995. In a series of 57 cases of adult ALCL, including T-cell and null cell phenotypes, 5-year overall survival (OS) was 67%. When stratified for expression of ALK, there was a significant favorable prognosis with ALK positivity, with a 5-year OS of 93% vs 37% (P < .00001) and 5-year FFS of 88% vs 37% (P < .0001). The report by Savage et al confirmed the superior survival of systemic ALK+ ALCL compared with ALK-negative cases (5-year failure-free survival [FFS] 60% vs 36%; P = .015; and 5-year OS 70% vs 49%; P = .016); as previously discussed, however, ALK-positive patients were significantly younger than ALK-negative patients. Moreover, when they limited the survival comparison of ALK-negative and -positive cases to patients older or younger than 40 years of age, there were no differences in FFS or OS.
When histologic subgroups within T-cell lymphoma are compared, most reports have shown that the survival of systemic ALCL is superior to survival of PTCL-NOS. Further, patients with systemic ALK-negative ALCL have a slightly improved survival compared with those who have PTCL-NOS, although not all analyses support this. Savage et al showed that, compared with patients who had PTCL-NOS, ALK-negative ALCL patients treated with curative intent had an improved 5-year FFS (39% vs 20%; P = .011) and 5-year OS (51% vs 32%; P = .028).
The International Prognostic Index (IPI) is an independent prognostic marker that predicts survival in multivariate analysis across all peripheral T-cell lymphomas, including ALCL. It identifies high-risk groups within both the ALK+ and ALK− ALCL subgroups (Table 1). Another prognostic tool known as the ‘prognosis in T-cell lymphoma’ (PIT) scoring system was originally devised for PTCL-NOS patients; it incorporates age, performance status, LDH, and bone marrow involvement. The PIT has also shown to be predictive of progression-free survival (PFS) and OS in ALCL. In addition, expression of CD56, a neural cell adhesion molecule, was shown in a series of 143 patients with ALCL to be a predictor of poor survival (approximate 5-year OS: 28% vs 65%, P = .002). The inferior outcome associated with CD56 was seen with ALK+ and ALK− patients.
1. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 89:3909-3918, 1997.
2. The International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008.
3. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985.
4. Swerdlow S, Campo E, Harris N, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France, IARC Press, 2008.
5. Stein H, Foss HD, Durkop H, et al: CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 96:3681-3695, 2000.
6. Fischer P, Nacheva E, Mason DY, et al: A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin’s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 72:234-240, 1988.
7. Mason DY, Bastard C, Rimokh R, et al: CD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161-168, 1990.
8. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281-1284, 1994.
9. Savage KJ, Harris NL, Vose JM, et al: ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008.
10. Querfeld C, Kuzel TM, Guitart J, et al: Primary cutaneous CD30+ lymphoproliferative disorders: New insights into biology and therapy. Oncology (Williston Park) 21:689-696; discussion 699-700, 2007.
11. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.
12. Kumar S, Pittaluga S, Raffeld M, et al: Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: Report of 4 cases and review of the literature. Pediatr Dev Pathol 8:52-60, 2005.
13. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653-3661, 2000.
14. Woo DK, Jones CR, Vanoli-Storz MN, et al: Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Characterization of clinical subset with worse outcome. Arch Dermatol 145:667-674, 2009.
15. Natkunam Y, Warnke RA, Haghighi B, et al: Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: Clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol 27:392-399, 2000.
16. Kempf W, Levi E, Kamarashev J, et al: Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 29:295-300, 2002.
17. Melnyk A, Rodriguez A, Pugh WC, et al: Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 89:4514-4520, 1997.
18. Pellatt J, Sweetenham J, Pickering RM, et al: A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin’s lymphoma. Ann Hematol 81:267-272, 2002.
19. Falini B, Pileri S, Zinzani PL, et al: ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 93:2697-2706, 1999.
20. Suzuki R, Kagami Y, Takeuchi K, et al: Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993-3000, 2000.
21. ten Berge RL, de Bruin PC, Oudejans JJ, et al: ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462-469, 2003.
22. Takahashi D, Nagatoshi Y, Nagayama J, et al: Anaplastic large cell lymphoma in leukemic presentation: A case report and a review of the literature. J Pediatr Hematol Oncol 30:696-700, 2008.
23. de Jong D, Vasmel WL, de Boer JP, et al: Anaplastic large-cell lymphoma in women with breast implants. JAMA 300:2030-2035, 2008.
24. Shiota M, Nakamura S, Ichinohasama R, et al: Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954-1960, 1995.
25. Gascoyne RD, Aoun P, Wu D, et al: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999.
26. Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76-82, 1998.
27. Sonnen R, Schmidt WP, Muller-Hermelink HK, et al: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 129:366-372, 2005.
28. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
29. Boudova L, Kazakov DV, Jindra P, et al: Primary cutaneous histiocyte and neutrophil-rich CD30+ and CD56+ anaplastic large-cell lymphoma with prominent angioinvasion and nerve involvement in the forehead and scalp of an immunocompetent woman. J Cutan Pathol 33:584-589, 2006.
30. Lin JH, Lee JY: Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia. J Cutan Pathol 31:458-461, 2004.
31. Kummer JA, Vermeer MH, Dukers D, et al: Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 109:636-640, 1997.
32. Benner MF, Jansen PM, Meijer CJ, et al: Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 161:121-127, 2009.
33. Greisser J, Doebbeling U, Roos M, et al: Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 14:380-385, 2005.
34. Paulli M, Berti E, Boveri E, et al: Cutaneous CD30+ lymphoproliferative disorders: Expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 29:1223-1230, 1998.
35. Wahl AF, Klussman K, Thompson JD, et al: The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res 62:3736-3742, 2002.
36. Mori M, Manuelli C, Pimpinelli N, et al: CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. Blood 94:3077-3083, 1999.
37. Mao X, Orchard G, Lillington DM, et al: Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 37:176-185, 2003.
38. Herbst H, Sander C, Tronnier M, et al: Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol 137:680-686, 1997.
39. van Kester MS, Tensen CP, Vermeer MH, et al: Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol 130:563-575, 2010.
40. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al: ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91:2076-2084, 1998.
41. Delsol G, Falini B, Muller-Hermelink HK et al: Anaplastic large cell lymphoma (ALCL), ALK-positive, in: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4th ed. Lyon, WHO Press, 2008.
42. Pulford K, Lamant L, Morris SW, et al:Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394-1404, 1997.
43. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 267:316-317, 1995.
44. Salaverria I, Bea S, Lopez-Guillermo A, et al:. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 140:516-526, 2008.
45. Falini B, Bigerna B, Fizzotti M, et al: ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol 153:875-886, 1998.
46. Griffin CA, Hawkins AL, Dvorak C, et al: Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 59:2776-2780, 1999.
47. Lamant L, Pulford K, Bischof D, et al: Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156:1711-1721, 2000.
48. Soda M, Choi YL Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566, 2007.
49. Inghirami G, Macri L, Cesarman E, et al: Molecular characterization of CD30+ anaplastic large-cell lymphoma: High frequency of c-myc proto-oncogene activation. Blood 83:3581-3590, 1994.
50. Bai RY, Ouyang T, Miething C, et al: Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96:4319-4327, 2000.
51. Chiarle R, Voena C, Ambrogio C, et al: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23, 2008.
52. Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 40:244-256, 2003.
53. Vonderheid EC, Sajjadian A, Kadin ME: Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 34:470-481, 1996.
54. Tilly H, Gaulard P, Lepage E, et al: Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 90:3727-3734, 1997.
55. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 104:626-633, 2004.
56. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
57. Escalon MP, Liu NS, Yang Y, et al: Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: The M. D. Anderson Cancer Center experience. Cancer 103:2091-2098, 2005.
58. Jagasia M, Morgan D, Goodman S, et al: Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk Lymphoma 45:2261-2267, 2004.
59. Jantunen E, Wiklund T, Juvonen E, et al: Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: A nation-wide survey. Bone Marrow Transplant 33:405-410, 2004.
60. Song KW, Mollee P, Keating A, et al: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: Variable outcome according to pathological subtype. Br J Haematol 120:978-985, 2003.
61. Fanin R, Ruiz de Elvira MC, Sperotto A, et al: Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 23:437-442, 1999.
62. Rodriguez J, Conde E, Gutierrez A, et al: The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 92:1067-1074, 2007.
63. Smith SD, Bolwell BJ, Rybicki LA, et al: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 40:239-243, 2007.
64. Deconinck E, Lamy T, Foussard C, et al: Autologous stem cell transplantation for anaplastic large-cell lymphomas: Results of a prospective trial. Br J Haematol 109:736-742, 2000.
65. Fanin R, Silvestri F, Geromin A, et al: Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation. Blood 87:1243-1248, 1996.
66. Fanin R, Sperotto A, Silvestri F, et al: The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: Results of 40 cases treated in a single center. Leuk Lymphoma 35:159-169, 1999.
67. Corradini P, Tarella C, Zallio F, et al: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533-1538, 2006.
68. Reimer P, Rudiger T, Geissinger E, et al: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. J Clin Oncol 27:106-113, 2009.
69. Rodriguez J, Conde E, Gutierrez A, et al: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from the GEL-TAMO Study Group. Eur J Haematol 79:32-38, 2007.
70. Mercadal S, Briones J, Xicoy B, et al: Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958-963, 2008.
71. Nickelsen M, Ziepert M, Zeynalova S, et al: High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: A comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977-1984, 2009.
72. Dhedin N, Giraudier S, Gaulard P, et al: Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 107:154-161, 1999.
73. Le Gouill S, Milpied N, Buzyn A, et al: Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264-2271, 2008.
74. Corradini P, Dodero A, Zallio F, et al: Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004.
75. Gallamini A, Zaja F, Patti C, et al: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007.
76. National Institutes of Health: A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma. Last updated June 5, 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00337987. Accessed May 19, 2010.
77. National Cancer Institute: Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms. Last updated April 22, 2009. Available at: http://clinicaltrials.gov/ct2/show/NCT00217425. Accessed May 19, 2010.
78. Lee J, Suh C, Kang HJ, et al: Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann Oncol 19:2079-2083, 2008.
79. O’Connor OA, Horwitz S, Hamlin P, et al: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 27:4357-4364, 2009.
80. Brugieres L, Pacquement H, Le Deley MC, et al: Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: A report from the French Society of Pediatric Oncology. J Clin Oncol 27:5056-5061, 2009.
81. Gualco G, Chioato L, Weiss LM, et al: Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol 132:28-33, 2009.
82. Janik JE, Morris JC, Pittaluga S, et al: Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. Blood 104:3355-3357, 2004.
83. Borchmann P, Treml JF, Hansen H, et al: The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102:3737-3742, 2003.
84. Ansell SM, Horwitz SM, Engert A, et al:Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764-2769, 2007.
85. Cardarelli PM, Moldovan-Loomis MC, Preston B, et al: In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res 15:3376-3383, 2009.
86. Forero-Torres A, Leonard JP, Younes A, et al: A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171-179, 2009.
87. Duvic M, Reddy SA, Pinter-Brown L, et al: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217-6224, 2009.
88. Francisco JA, Cerveny CG, Meyer DL, et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465, 2003.
89. Younes A F-TA, Bartlett NL: Multiple complete responses in a phase I dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractoryCD-30 positive lymphomas (abstract 1006). Presented at the American Society of Hematology 50th annual meeting, San Francisco, CA, December 6–9, 2008. Available at http://ash.confex.com/ash/2008/webprogram/Paper8532.html. Accessed May 21, 2010.
90. Bartlett NL F-TA, Rosenblatt JD: Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin Lymphoma (HL) or systemic anaplastic large cell lymphoma (abstract 8500). Presented at the 2009 annual meeting of the American Society of Clinical Oncology, Orlando, FL, May 29–June 2, 2009. Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c.... Accessed May 21, 2010.
91. National Institutes of Health: A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma. Available at http://clinicaltrials.gov/ct2/show/study/NCT00866047?show_locs=Y#locn. Accessed May 21, 2010.
92. Gopal AK, Pagel JM, Fromm JR, et al: 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood 113:5905-5910, 2009.
93. Schnell R, Dietlein M, Staak JO, et al: Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23:4669-4678, 2005
94. Dancey G, Violet J, Malaroda A, et al: A phase I clinical trial of CHT-25, a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res 15:7701-7710, 2009.
95. Foss FM, Raubitscheck A, Mulshine JL, et al: Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res 4:2691-2700, 1998.
96. Waldmann TA, White JD, Carrasquillo JA, et al: Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86:4063-4075, 1995.
97. Woo S, Gardner ER, Chen X, et al: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 15:1496-1503, 2009.
98. Piekarz R, Wright J, Frye R, et al: Results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL) (abstract 1657). Blood 114:661, 2009.
99. Zhao WL, Liu YY, Zhang QL, et al: PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor. Blood 111:3867-3871, 2008.
100. Mathas S, Johrens K, Joos S, et al: Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106:4287-4293, 2005.
101. Zinzani PL, Musuraca G, Tani M, et al: Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25:4293-4297, 2007.
102. Evens AM GL, Gordon LI, Patton D, et al: Phase I results of combination gemcitabine and bortezomib (Velcade®) for relapsed/refractory nodal T-cell non-Hodgkin lymphoma (T-NHL) and aggressive B-cell NHL (abstract 2005). Presented at the American Society of Hematology 50th annual meeting, San Francisco, CA, December 6–9, 2008. Available at http://ash.confex.com/ash/2008/webprogram/Paper11233.html. Accessed May 21, 2010.
103. Heider U, Rademacher J, Lamottke B, et al: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 82:440-449, 2009.
104. Zhang QL, Wang L, Zhang YW, et al: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23:1507-1514, 2009.
105. National Institutes of Health: Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin’s Lymphoma. Available at: http://www.clinicaltrial.gov/ct2/show/NCT00810576. Accessed May 21, 2010.
106. Damaj G, Bouabdallah R, Vey N, et al: Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol 74:169-171, 2005.
107. Dueck GS, Chua N, Prasad A, et al: Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases (abstract 8524). J Clin Oncol 27(suppl):15s, 2009. Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&c.... Accessed May 21, 2010.
108. National Institutes of Health: A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma. Available at http://clinicaltrials.gov/ct2/show/NCT00322985. Accessed May 21, 2010.
109. Li R, Morris SW: Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28:372-412, 2008.
110. McDermott U, Iafrate AJ, Gray NS, et al: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395, 2008.
111. Galkin AV, Melnick JS, Kim S, et al: Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104:270-275, 2007.
112. Christensen JG, Zou HY, Arango ME, et al: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314-3322, 2007.
113. Bonvini P, Dalla Rosa H, Vignes N, et al: Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: Role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 64:3256-3264, 2004.
114. Lu L, Ghose AK, Quail MR, et al: ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 48:3600-3609, 2009.
115. Han Y, Amin HM, Frantz C, et al: Restoration of SHP1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 20:1602-1609, 2006.
116. Bonvini P, Zorzi E, Mussolin L, et al: The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica 94:944-955, 2009.
117. Drakos E, Atsaves V, Schlette E, et al: The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 23:2290-2299, 2009.
118. Boccalatte FE, Voena C, Riganti C, et al: The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: New insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood 113:2776-2790, 2009.